Tang Shengbo, Yuan Xihong, Song Jintian, Chen Yigui, Tan Xiaojie, Li Qiyun
Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China.
Department of General and Abdominal Surgery, Jiangxi Provincial People's Hospital, Nanchang, Jiangxi 330006, P.R. China.
Oncol Lett. 2019 Jan;17(1):159-164. doi: 10.3892/ol.2018.9569. Epub 2018 Oct 12.
The present study investigated the association between the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway with tumor progression and prognosis of colon cancer. A total of 62 patients with colon cancer were selected as the colon cancer group, and 40 patients with colon lesions were selected as the benign colon lesion group. Immunohistochemistry was used to detect the expression levels of JAK-1 and STAT-3 proteins in colon tissues. The association of JAK-1 and STAT-3 proteins with the pathological parameters and prognosis of colon cancer were analyzed. The total positive rates of JAK-1 and STAT-3 proteins in lesions of patients in the colon cancer group were significantly higher compared with those in the benign colon lesion group (P<0.05). The positive expression of JAK-1 and STAT-3 proteins in patients with colon cancer were not significantly associated with sex, age, tumor differentiation degree and neurovascular invasion (P>0.05), but significantly associated with the clinical stage of colon cancer, tumor infiltration depth and lymph node metastasis (P<0.05). The survival time of patients with colon cancer with positively-expressed JAK-1 and STAT-3 proteins was significantly shorter compared with that of patients with negatively-expressed JAK-1 and STAT-3 proteins (P<0.05). tumor-node-metastasis (TNM) stage, lymph node metastasis and the expression of JAK-1 and STAT-3 proteins in the tumor were associated with the prognosis of patients with colon cancer (P<0.05). TNM stage and the expression levels of JAK-1 and STAT-3 proteins were independent risk factors influencing the prognosis of colon cancer (P<0.05). The JAK/STAT signal may be used as a novel tumor marker and prognostic factor for the diagnosis, assessment and prognosis of colon cancer.
本研究探讨了Janus激酶/信号转导子和转录激活子（JAK/STAT）信号通路与结肠癌肿瘤进展及预后之间的关联。共选取62例结肠癌患者作为结肠癌组，40例结肠病变患者作为良性结肠病变组。采用免疫组织化学法检测结肠组织中JAK-1和STAT-3蛋白的表达水平。分析JAK-1和STAT-3蛋白与结肠癌病理参数及预后的相关性。结肠癌组患者病变中JAK-1和STAT-3蛋白的总阳性率显著高于良性结肠病变组（P<0.05）。结肠癌患者中JAK-1和STAT-3蛋白的阳性表达与性别、年龄、肿瘤分化程度及神经血管侵犯无显著相关性（P>0.05），但与结肠癌的临床分期、肿瘤浸润深度及淋巴结转移显著相关（P<0.05）。JAK-1和STAT-3蛋白表达阳性的结肠癌患者的生存时间显著短于JAK-1和STAT-3蛋白表达阴性的患者（P<0.05）。肿瘤-淋巴结-转移（TNM）分期、淋巴结转移以及肿瘤中JAK-1和STAT-3蛋白的表达与结肠癌患者的预后相关（P<0.05）。TNM分期以及JAK-1和STAT-3蛋白的表达水平是影响结肠癌预后的独立危险因素（P<0.05）。JAK/STAT信号可能作为一种新型肿瘤标志物和预后因素用于结肠癌的诊断、评估及预后判断。
